Craft

ThermoGenesis

Stock Price

$0

2024-10-29

Market Capitalization

$9.5 K

2024-10-29

Revenue

$9.4 M

FY, 2023

ThermoGenesis Summary

Company Summary

Overview
ThermoGenesis Holdings (formerly known as Cesca Therapeutics) is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. ThermoGenesis’s clinical development division is leveraging its proprietary AutoXpress technology platform to develop stem cell-based therapies in the immuno-oncology, vascular, cardiology and orthopedic markets.
Type
Public
Status
Active
Founded
1986
HQ
Rancho Cordova, CA, US | view all locations
Website
https://thermogenesis.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Chris Xu

    Chris Xu, Chairman and Chief Executive Officer

    • Haihong Zhu

      Haihong Zhu, Chief Operating Officer, Director

    • Russell Medford
    • Jeff Cauble

      Jeff Cauble, Chief Financial Officer

    Operating MetricsView all

    Patents Issued

    25

    FY, 2016

    LocationsView all

    2 locations detected

    • Rancho Cordova, CA HQ

      United States

      2711 Citrus Rd

    • Wuxi Shi, Jiangsu Sheng

      China

      800 Jiefang E Rd, Zhong Shan Lu, Liangxi Qu

    ThermoGenesis Financials

    Summary Financials

    Revenue (Q1, 2024)
    $2.7M
    Gross profit (Q1, 2024)
    $1.2M
    Net income (Q1, 2024)
    ($2.0M)
    Cash (Q1, 2024)
    $1.2M
    EBIT (Q1, 2024)
    ($557.0K)
    Enterprise value
    $5.8M

    Footer menu